A team of scientists from La Trobe University has shown a protein found in a tobacco plant has the potential to fight life-threatening infectious diseases
The scientific discovery, published in the prestigious journal Nature Communications could lead to the development of a new class of antibiotics and meet the challenge of rising antibiotic resistance.
Dr Mark Hulett and Dr Marc Kvansakul from the La Trobe Institute for Molecular Science said their team had demonstrated the peptide NaD1 found in the flowers of the ornamental tobacco plant Nicotiana alata has infection-busting qualities.
“Infectious diseases are a major global health problem, accounting for more than one in eight deaths and mortality rates are predicted to skyrocket over the next 30 years,” Dr Hulett said.
“Antibiotic resistance at the current rate will eventually lead to the exhaustion of effective long-term drug options. It’s imperative we develop new antibiotic treatments.”
Using the power of the Australian Synchrotron, the team led by Dr Hulett and Dr Kvansakul have shown in atomic detail how the tobacco plant peptide can target and destroy the micro-organism responsible for a dangerous fungal infection.
The peptide perforates the parachute-like outer layer of Candida albicans cells, ripping them apart and causing them to explode and die.
“They act in a different way to existing antibiotics and allow us to explore new ways of fighting infections.
“It’s an exciting discovery that could be harnessed to develop a new class of life-saving antimicrobial therapy to treat a range of infectious diseases, including multi-drug-resistant golden staph, and viral infections such as HIV, Zika virus, Dengue and Murray River Encephalitis.”
In 2014, Dr Hulett and Dr Kvansakul found NaD1 could also be effective in killing cancer cells.
Candida albicans is responsible for life-threatening infections in immune-compromised patients, including those diagnosed with cancer and transplant recipients. There are limited effective antibiotics available to treat the infection.
Nicotiana alata flowers naturally produce potent anti-fungal molecules for protection against disease. The plant is related, but different, to tobacco plants grown for commercial use.
Learn more: La Trobe’s infection-busting discovery
The Latest on: Antimicrobial therapy
via Google News
The Latest on: Antimicrobial therapy
Lilly to Unveil New Data at the Annual European Congress of Rheumatology, Furthering Commitment to Scientific Discovery in Immunology
on June 11, 2018 at 3:58 am
Tuberculosis – Before initiating OLUMIANT, evaluate and test patients for latent or active infection and treat patients with latent TB with standard antimicrobial therapy. OLUMIANT should not be given to patients with active TB. Consider anti-TB therapy ... […]
Bacteriophage Therapy Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024
on June 7, 2018 at 8:27 am
Bacteriophage therapy or phage therapy is used to treat the pathogenic ... In March 2017, Intralytix, Inc. received GRAS recognition from FDA for ShigaShield, a non-chemical antimicrobial preparation to control waterborne/foodborne bacterial pathogen ... […]
Antimicrobial therapy can prevent sepsis in pneumonia patients
on April 16, 2018 at 8:04 am
Antimicrobial therapy targeting specific cells in the immune system could prevent sepsis and life-threatening disease in people suffering from pneumonia, new research led by the University of Leicester has shown. An antimicrobial therapy kills or inhibits ... […]
Blog Exposure - FDA Granted New 510(k) Clearance to Sonoma Pharma’s Antimicrobial Post-Therapy Gel
on April 9, 2018 at 5:48 am
LONDON, UK / ACCESSWIRE / April 09, 2018 / Active-Investors.com has just released a free research report on Sonoma Pharma, Inc. (NASDAQ: SNOA). If you want access to this report all you need to do is sign up now by clicking the following link www.active ... […]
FDA clears Sonoma Pharma's antimicrobial post-therapy gel
on April 5, 2018 at 4:11 pm
The FDA grants 510(k) clearance for Sonoma Pharmaceuticals' (NASDAQ:SNOA) antimicrobial post-therapy gel for the management of post-non-ablative laser therapy procedures, post-microdermabrasion therapy and following superficial chemical peels. The company ... […]
Sonoma Pharmaceuticals Announces FDA Approval for Antimicrobial Post-Therapy Gel
on April 5, 2018 at 4:25 am
April 05, 2018 07:05 ET | Source: Sonoma Pharmaceuticals, Inc. PETALUMA, Calif., April 05, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and ... […]
on February 15, 2018 at 4:00 am
Antimicrobial resistance (AMR ... In 2010, an estimated 7% of people starting antiretroviral therapy (ART) in developing countries had drug-resistant HIV. In developed countries, the same figure was 10–20%. Some countries have recently reported levels ... […]
Failure of dual antimicrobial therapy for gonorrhea reported
on June 23, 2016 at 11:40 am
(HealthDay)—In a case report published in the June 23 issue of the New England Journal of Medicine, dual antimicrobial therapy failure is described in the treatment of gonorrhea. Helen Fifer, B.M.B.S., from Public Health England in London, and colleagues ... […]
via Bing News